在胃癌中,外科手术与全新辅助化学疗法对比
Jessica Yang1,2, Megan Greally3, Vivian E Strong4
1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Journal of gastrointestinal oncology
|July 12, 2023
概括
胃癌 (GC) 的全新辅助疗法 (TNT) 在精选患者中是可行的,可能在不增加手术风险的情况下改善化疗. 由于样本规模较小,需要进行进一步的研究.
科学领域:
- 在瘤学瘤学.
- 手术瘤学手术瘤学
- 胃肠病学 胃肠病学
背景情况:
- 术后化学疗法是局部晚期胃癌 (GC) 的标准.
- 由于术后并发症,许多患者无法完成辅助治疗.
- 总的新辅助疗法 (TNT) 可以改善手术前的全身治疗完成.
研究的目的:
- 评估全新辅助疗法 (TNT) 的可行性和结果,与胃癌的外科化疗相比.
- 评估接受TNT与外科化疗的GC患者的治疗完成率,手术结果和生存率.
主要方法:
- 在2014年5月至2020年6月期间,149名胃癌患者在纪念斯隆凯特林癌症中心 (MSKCC) 接受治疗.
- 121名接受外科手术前化疗的患者与28名接受全新辅助疗法 (TNT) 的患者进行了比较.
- 分析基线特征,化疗治疗,治疗完成,手术发病率和生存结果.
主要成果:
- 在TNT患者中,所有计划使用的药物中,化学疗法周期的比例更高 (93%对74%).
- 在住院时间,手术发病率或病理完整反应率方面没有发现显著差异.
- 没有复发的生存率和整体生存率在TNT和术后组之间没有显著差异.
结论:
- 总的新辅助疗法 (TNT) 在精选的胃癌患者群体中是可行的.
- 与外科化疗相比,TNT并没有增加外科病率.
- 限制包括一个小的TNT样本大小和回顾性设计,需要进一步调查.
更多相关视频
03:32Single Incision Plus One Port Laparoscopic Proximal Gastrectomy with Double Channel Anastomosis for Gastric Cancer Treatment
Published on: December 27, 2024
824
13:37A Mouse Tumor Model of Surgical Stress to Explore the Mechanisms of Postoperative Immunosuppression and Evaluate Novel Perioperative Immunotherapies
Published on: March 12, 2014
30.1K
相关概念视频
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
204
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
204
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
249
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
249